Leadless left ventricular endocardial pacing for CRT upgrades in previously failed and high-risk patients in comparison with coronary sinus CRT upgrades.
Cardiac resynchronization therapy
Endocardial pacing
Epicardial pacing
WiSE-CRT system
Journal
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649
Informations de publication
Date de publication:
09 10 2021
09 10 2021
Historique:
received:
09
03
2021
pubmed:
30
7
2021
medline:
21
10
2021
entrez:
29
7
2021
Statut:
ppublish
Résumé
Cardiac resynchronization therapy (CRT) upgrades may be less likely to improve following intervention. Leadless left ventricular (LV) endocardial pacing has been used for patients with previously failed CRT or high-risk upgrades. We compared procedural and long-term outcomes in patients undergoing coronary sinus (CS) CRT upgrades with high-risk and previously failed CRT upgrades undergoing LV endocardial upgrades. Prospective consecutive CS upgrades between 2015 and 2019 were compared with those undergoing WiSE-CRT implantation. Cardiac resynchronization therapy response at 6 months was defined as improvement in clinical composite score (CCS) and a reduction in LV end-systolic volume (LVESV) ≥15%. A total of 225 patients were analysed; 121 CS and 104 endocardial upgrades. Patients receiving WiSE-CRT tended to have more comorbidities and were more likely to have previous cardiac surgery (30.9% vs. 16.5%; P = 0.012), hypertension (59.2% vs. 34.7%; P < 0.001), chronic obstructive airways disease (19.4% vs. 9.9%; P = 0.046), and chronic kidney disease (46.4% vs. 21.5%; P < 0.01) but similar LV ejection fraction (30.0 ± 8.3% vs. 29.5 ± 8.6%; P = 0.678). WiSE-CRT upgrades were successful in 97.1% with procedure-related mortality in 1.9%. Coronary sinus upgrades were successful in 97.5% of cases with a 2.5% rate of CS dissection and 5.6% lead malfunction/displacement. At 6 months, 91 WiSE-CRT upgrades and 107 CS upgrades had similar improvements in CCS (76.3% vs. 68.5%; P = 0.210) and reduction in LVESV ≥15% (54.2% vs. 56.3%; P = 0.835). Despite prior failed upgrades and high-risk patients with more comorbidities, WiSE-CRT upgrades had high rates of procedural success and similar improvements in CCS and LV remodelling with CS upgrades.
Identifiants
pubmed: 34322707
pii: 6329891
doi: 10.1093/europace/euab156
pmc: PMC8502498
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1577-1585Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Pacing Clin Electrophysiol. 2016 Jun;39(6):531-41
pubmed: 27001004
Expert Rev Cardiovasc Ther. 2018 Aug;16(8):607-615
pubmed: 29985076
J Am Coll Cardiol. 2017 May 2;69(17):2119-2129
pubmed: 28449772
Pacing Clin Electrophysiol. 2020 Sep;43(9):966-973
pubmed: 32330307
J Card Fail. 2001 Jun;7(2):176-82
pubmed: 11420770
Europace. 2020 Nov 1;22(11):1718-1728
pubmed: 32688392
Europace. 2012 Sep;14(9):1236-86
pubmed: 22930717
Europace. 2018 Nov 1;20(11):1733-1740
pubmed: 29452360
JACC Clin Electrophysiol. 2021 Jul;7(7):871-880
pubmed: 33640347
Heart Rhythm. 2017 Jul;14(7):1043-1050
pubmed: 28214565
Expert Rev Med Devices. 2018 Aug;15(8):555-570
pubmed: 30019954
Eur Heart J. 2016 Jul 14;37(27):2118-27
pubmed: 26787437
J Am Coll Cardiol. 2019 Nov 26;74(21):2588-2603
pubmed: 31748196
Eur J Heart Fail. 2011 Sep;13(9):974-83
pubmed: 21771823
Europace. 2014 May;16(5):681-8
pubmed: 24497573
Circ Arrhythm Electrophysiol. 2017 Feb;10(2):e004471
pubmed: 28202628
Europace. 2020 Feb 1;22(2):298
pubmed: 31504436
Europace. 2013 Aug;15(8):1070-118
pubmed: 23801827
J Am Coll Cardiol. 2017 May 16;69(19):2369-2379
pubmed: 28494974
Heart Rhythm. 2020 Aug;17(8):1291-1297
pubmed: 32165181